MedTrace Logo

American Hepato-Pancreato-Biliary Association (AHPBA) Pancreatic Irreversible Electroporation (IRE) Registry

NCT02674100 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2025-02-25

No results posted yet for this study

Summary

The purpose of this study is to create a registry to provide insight into treatment selection and treatment outcome of pancreatic IRE in order to develop an evidence base such that physicians can provide the best possible care to patients with pancreatic cancer requiring surgical interventions.

The investigators seek a better understanding of the uses of ablation in the treatment of unresectable soft tissue pancreatic tumors and the limitations, concerns and complications that earlier users have.

Conditions

Interventions

OTHER

Registry

Sponsors & Collaborators

  • The Americas Hepato-Pancreato-Biliary Association

    collaborator UNKNOWN

  • University of Louisville

    lead OTHER

Principal Investigators

  • Robert Martin, MD, PhD · University of Louisville

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2030-01-31
Completion
2030-01-31

Countries

  • United States
  • Canada
  • Japan
  • Mexico
  • Taiwan
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02674100 on ClinicalTrials.gov